Profitability ratios measure the company ability to generate profitable sales from its resources (assets).
Profitability Ratios (Summary)
Return on Sales
Return on Investment
Based on: 10-K (reporting date: 2022-09-30), 10-K (reporting date: 2021-09-30), 10-K (reporting date: 2020-09-30), 10-K (reporting date: 2019-09-30), 10-K (reporting date: 2018-09-30), 10-K (reporting date: 2017-09-30).
The profitability profile reflects a high-volume, low-margin operational model characterized by narrow spreads and significant volatility during the 2020 fiscal period. While most metrics experienced a sharp contraction in 2020, a general recovery trend is observed in the subsequent two years, with margins returning to or exceeding pre-2020 levels.
- Profit Margins
- Gross profit margins remained relatively stable between 2.73% and 2.97% from 2017 to 2020, followed by a notable increase to 3.24% in 2021 and 3.48% in 2022. In contrast, operating and net profit margins exhibited greater volatility. Both metrics declined sharply in 2020, with the operating margin falling to -2.70% and the net margin to -1.80%. A recovery occurred in 2021, with the operating margin rebounding to 1.10% and the net margin to 0.72%, remaining relatively flat through 2022.
- Return on Assets (ROA)
- The return on assets closely mirrors the trend observed in net profit margins. After peaking at 4.40% in 2018, the ROA declined to -7.70% in 2020. This downward trajectory reversed in 2021 and 2022, with the ratio climbing to 2.69% and 3.00% respectively, indicating a restoration of asset productivity.
- Return on Equity (ROE)
- Return on equity demonstrates extreme volatility and non-linear movement. After fluctuating between 17.66% and 56.55% from 2017 to 2019, the ratio reached an anomalous peak of 689.46% in 2021. This extreme spike suggests a significant reduction in the equity base or a substantial increase in financial leverage during that period, rather than a purely operational increase in profitability.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.
How can I help you?
Gross Profit Margin
| Sep 30, 2022 | Sep 30, 2021 | Sep 30, 2020 | Sep 30, 2019 | Sep 30, 2018 | Sep 30, 2017 | ||
|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | |||||||
| Gross profit | 8,296,367) | 6,943,228) | 5,191,884) | 5,138,312) | 4,612,317) | 4,546,002) | |
| Revenue | 238,587,006) | 213,988,843) | 189,893,926) | 179,589,121) | 167,939,635) | 153,143,826) | |
| Profitability Ratio | |||||||
| Gross profit margin1 | 3.48% | 3.24% | 2.73% | 2.86% | 2.75% | 2.97% | |
| Benchmarks | |||||||
| Gross Profit Margin, Competitors2 | |||||||
| Abbott Laboratories | 51.54% | 52.21% | — | — | — | — | |
| Elevance Health Inc. | 16.79% | 17.09% | — | — | — | — | |
| Intuitive Surgical Inc. | 67.44% | 69.32% | — | — | — | — | |
| Medtronic PLC | 67.98% | 65.19% | — | — | — | — | |
| UnitedHealth Group Inc. | 24.09% | 23.60% | — | — | — | — | |
Based on: 10-K (reporting date: 2022-09-30), 10-K (reporting date: 2021-09-30), 10-K (reporting date: 2020-09-30), 10-K (reporting date: 2019-09-30), 10-K (reporting date: 2018-09-30), 10-K (reporting date: 2017-09-30).
1 2022 Calculation
Gross profit margin = 100 × Gross profit ÷ Revenue
= 100 × 8,296,367 ÷ 238,587,006 = 3.48%
2 Click competitor name to see calculations.
The financial performance from September 30, 2017, to September 30, 2022, is characterized by consistent expansion in both top-line revenue and absolute gross profit, alongside a notable improvement in margin efficiency in the final two years of the observed period.
- Revenue and Gross Profit Growth
- Revenue exhibited a steady upward trajectory, increasing from 153.1 billion USD in 2017 to 238.6 billion USD in 2022. Parallel to this, gross profit rose from 4.5 billion USD to 8.3 billion USD. A significant acceleration in gross profit is observed after September 30, 2020, where the absolute increase in profit began to outpace the historical growth rates established between 2017 and 2020.
- Gross Profit Margin Volatility and Expansion
- The gross profit margin remained under 3% for the first four years of the period, fluctuating between a peak of 2.97% in 2017 and a low of 2.73% in 2020. A distinct trend reversal occurred in 2021, with the margin climbing to 3.24%, followed by a further increase to 3.48% in 2022. This represents a shift from a period of margin compression and stagnation to a period of margin expansion.
- Operational Efficiency Insights
- The divergence between the steady revenue growth and the accelerating gross profit margin after 2020 indicates an improvement in cost management or a strategic shift in the product mix toward higher-margin offerings. The fact that gross profit grew more rapidly than revenue in the final two years suggests that the company successfully enhanced its ability to convert sales into gross profit.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.
How can I help you?
Operating Profit Margin
| Sep 30, 2022 | Sep 30, 2021 | Sep 30, 2020 | Sep 30, 2019 | Sep 30, 2018 | Sep 30, 2017 | ||
|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | |||||||
| Operating income (loss) | 2,366,378) | 2,354,197) | (5,135,354) | 1,111,923) | 1,443,685) | 1,060,342) | |
| Revenue | 238,587,006) | 213,988,843) | 189,893,926) | 179,589,121) | 167,939,635) | 153,143,826) | |
| Profitability Ratio | |||||||
| Operating profit margin1 | 0.99% | 1.10% | -2.70% | 0.62% | 0.86% | 0.69% | |
| Benchmarks | |||||||
| Operating Profit Margin, Competitors2 | |||||||
| Abbott Laboratories | 19.16% | 19.56% | — | — | — | — | |
| Elevance Health Inc. | 4.94% | 5.15% | — | — | — | — | |
| Intuitive Surgical Inc. | 25.35% | 31.89% | — | — | — | — | |
| Medtronic PLC | 18.15% | 14.89% | — | — | — | — | |
| UnitedHealth Group Inc. | 8.83% | 8.40% | — | — | — | — | |
| Operating Profit Margin, Sector | |||||||
| Health Care Equipment & Services | 9.26% | 9.13% | — | — | — | — | |
| Operating Profit Margin, Industry | |||||||
| Health Care | 18.74% | 18.04% | — | — | — | — | |
Based on: 10-K (reporting date: 2022-09-30), 10-K (reporting date: 2021-09-30), 10-K (reporting date: 2020-09-30), 10-K (reporting date: 2019-09-30), 10-K (reporting date: 2018-09-30), 10-K (reporting date: 2017-09-30).
1 2022 Calculation
Operating profit margin = 100 × Operating income (loss) ÷ Revenue
= 100 × 2,366,378 ÷ 238,587,006 = 0.99%
2 Click competitor name to see calculations.
Revenue demonstrates a consistent upward trajectory, increasing from $153.1 billion in 2017 to $238.6 billion by 2022. Despite this steady growth in top-line performance, operating income exhibits significant volatility, characterized by a severe contraction in 2020 followed by a recovery and stabilization period in 2021 and 2022.
- Revenue and Operational Scale
- A sustained increase in business volume is observed, with revenue growing annually over the six-year period. This suggests a consistent expansion of market reach or pricing adjustments that successfully drove higher gross inflows.
- Operating Profit Margin Trends
- The operating profit margin remained narrow and relatively stable between 2017 and 2019, ranging from 0.62% to 0.86%. A significant anomaly occurred in 2020, where the margin plummeted to -2.70%, reflecting an operating loss of approximately $5.1 billion. This represents a substantial deviation from the established operational trend, indicating an extraordinary increase in operating expenses or a one-time impairment during that fiscal year.
- Recovery and Margin Normalization
- A strong recovery is evident in 2021, with the operating profit margin rebounding to 1.10%, the highest level in the observed period. By 2022, the margin normalized slightly to 0.99%. While the operating income in 2021 and 2022 ($2.35 billion and $2.37 billion, respectively) significantly exceeds the pre-2020 levels, the percentage margin remains thin, characteristic of high-volume, low-margin operational models.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.
How can I help you?
Net Profit Margin
| Sep 30, 2022 | Sep 30, 2021 | Sep 30, 2020 | Sep 30, 2019 | Sep 30, 2018 | Sep 30, 2017 | ||
|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | |||||||
| Net income (loss) attributable to AmerisourceBergen Corporation | 1,698,820) | 1,539,932) | (3,408,716) | 855,365) | 1,658,405) | 364,484) | |
| Revenue | 238,587,006) | 213,988,843) | 189,893,926) | 179,589,121) | 167,939,635) | 153,143,826) | |
| Profitability Ratio | |||||||
| Net profit margin1 | 0.71% | 0.72% | -1.80% | 0.48% | 0.99% | 0.24% | |
| Benchmarks | |||||||
| Net Profit Margin, Competitors2 | |||||||
| Abbott Laboratories | 15.88% | 16.42% | — | — | — | — | |
| Elevance Health Inc. | 3.87% | 4.46% | — | — | — | — | |
| Intuitive Surgical Inc. | 21.25% | 29.85% | — | — | — | — | |
| Medtronic PLC | 15.90% | 11.97% | — | — | — | — | |
| UnitedHealth Group Inc. | 6.25% | 6.06% | — | — | — | — | |
| Net Profit Margin, Sector | |||||||
| Health Care Equipment & Services | 7.05% | 7.14% | — | — | — | — | |
| Net Profit Margin, Industry | |||||||
| Health Care | 14.65% | 15.24% | — | — | — | — | |
Based on: 10-K (reporting date: 2022-09-30), 10-K (reporting date: 2021-09-30), 10-K (reporting date: 2020-09-30), 10-K (reporting date: 2019-09-30), 10-K (reporting date: 2018-09-30), 10-K (reporting date: 2017-09-30).
1 2022 Calculation
Net profit margin = 100 × Net income (loss) attributable to AmerisourceBergen Corporation ÷ Revenue
= 100 × 1,698,820 ÷ 238,587,006 = 0.71%
2 Click competitor name to see calculations.
The financial performance over the analyzed six-year period is characterized by consistent revenue expansion coupled with significant volatility in net income and profit margins.
- Revenue Trajectory
- A steady upward trend in revenue is observed, increasing from 153.1 billion US dollars in 2017 to 238.6 billion US dollars by 2022. This growth indicates a consistent increase in the scale of business operations throughout the period.
- Net Profit Margin Fluctuations
- The net profit margin remained consistently low, reflecting a high-volume, low-margin operational model. The margin peaked at 0.99% in 2018 but experienced a sharp decline to -1.80% in 2020. This negative margin corresponds with a substantial net loss of approximately 3.4 billion US dollars in that fiscal year, marking a significant departure from the surrounding years' performance.
- Recovery and Margin Stabilization
- A recovery in profitability occurred following the 2020 deficit. Net income returned to positive territory in 2021 and 2022, with the net profit margin stabilizing at 0.72% and 0.71%, respectively. By September 30, 2022, net income reached 1.7 billion US dollars, aligning closely with the performance levels seen in 2018 despite the significantly higher revenue base.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.
How can I help you?
Return on Equity (ROE)
| Sep 30, 2022 | Sep 30, 2021 | Sep 30, 2020 | Sep 30, 2019 | Sep 30, 2018 | Sep 30, 2017 | ||
|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | |||||||
| Net income (loss) attributable to AmerisourceBergen Corporation | 1,698,820) | 1,539,932) | (3,408,716) | 855,365) | 1,658,405) | 364,484) | |
| Total AmerisourceBergen Corporation stockholders’ equity (deficit) | (211,559) | 223,354) | (1,018,924) | 2,878,917) | 2,932,824) | 2,064,461) | |
| Profitability Ratio | |||||||
| ROE1 | — | 689.46% | — | 29.71% | 56.55% | 17.66% | |
| Benchmarks | |||||||
| ROE, Competitors2 | |||||||
| Abbott Laboratories | 18.90% | 19.75% | — | — | — | — | |
| Elevance Health Inc. | 16.59% | 16.93% | — | — | — | — | |
| Intuitive Surgical Inc. | 11.98% | 14.32% | — | — | — | — | |
| Medtronic PLC | 9.59% | 7.01% | — | — | — | — | |
| UnitedHealth Group Inc. | 25.87% | 24.09% | — | — | — | — | |
| ROE, Sector | |||||||
| Health Care Equipment & Services | 18.40% | 17.28% | — | — | — | — | |
| ROE, Industry | |||||||
| Health Care | 24.82% | 25.44% | — | — | — | — | |
Based on: 10-K (reporting date: 2022-09-30), 10-K (reporting date: 2021-09-30), 10-K (reporting date: 2020-09-30), 10-K (reporting date: 2019-09-30), 10-K (reporting date: 2018-09-30), 10-K (reporting date: 2017-09-30).
1 2022 Calculation
ROE = 100 × Net income (loss) attributable to AmerisourceBergen Corporation ÷ Total AmerisourceBergen Corporation stockholders’ equity (deficit)
= 100 × 1,698,820 ÷ -211,559 = —
2 Click competitor name to see calculations.
Financial performance between 2017 and 2022 is characterized by extreme volatility in net income and a significant erosion of stockholders' equity, leading to distorted profitability metrics.
- Net Income Trends
- Earnings experienced substantial fluctuations, starting at 364.5 million in 2017 and peaking at 1.66 billion in 2018. A severe downturn occurred in 2020, resulting in a net loss of 3.41 billion. However, a recovery phase followed, with net income returning to positive territory at 1.54 billion in 2021 and increasing to 1.70 billion by 2022.
- Equity Position and Capital Structure
- Stockholders' equity demonstrated a precarious downward trend. After peaking at 2.93 billion in 2018, equity collapsed into a deficit of 1.02 billion by 2020. Although a brief recovery to 223 million was recorded in 2021, the position reverted to a deficit of 211.6 million in 2022. This suggests a capital structure heavily reliant on liabilities or influenced by significant treasury stock repurchases and losses.
- Return on Equity (ROE) Interpretation
- ROE values are highly unstable due to the volatility of the equity base. The ratio increased from 17.66% in 2017 to 56.55% in 2018, before settling at 29.71% in 2019. The reported ROE of 689.46% in 2021 is an outlier caused by the mathematical effect of dividing a recovering net income by a critically low equity base, rather than an indicator of operational efficiency. In 2020 and 2022, the presence of negative equity rendered the ROE metric non-representative of standard profitability.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.
How can I help you?
Return on Assets (ROA)
| Sep 30, 2022 | Sep 30, 2021 | Sep 30, 2020 | Sep 30, 2019 | Sep 30, 2018 | Sep 30, 2017 | ||
|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | |||||||
| Net income (loss) attributable to AmerisourceBergen Corporation | 1,698,820) | 1,539,932) | (3,408,716) | 855,365) | 1,658,405) | 364,484) | |
| Total assets | 56,560,616) | 57,337,805) | 44,274,830) | 39,171,980) | 37,669,838) | 35,316,470) | |
| Profitability Ratio | |||||||
| ROA1 | 3.00% | 2.69% | -7.70% | 2.18% | 4.40% | 1.03% | |
| Benchmarks | |||||||
| ROA, Competitors2 | |||||||
| Abbott Laboratories | 9.31% | 9.40% | — | — | — | — | |
| Elevance Health Inc. | 5.86% | 6.26% | — | — | — | — | |
| Intuitive Surgical Inc. | 10.19% | 12.58% | — | — | — | — | |
| Medtronic PLC | 5.54% | 3.87% | — | — | — | — | |
| UnitedHealth Group Inc. | 8.19% | 8.15% | — | — | — | — | |
| ROA, Sector | |||||||
| Health Care Equipment & Services | 7.49% | 7.28% | — | — | — | — | |
| ROA, Industry | |||||||
| Health Care | 9.66% | 9.46% | — | — | — | — | |
Based on: 10-K (reporting date: 2022-09-30), 10-K (reporting date: 2021-09-30), 10-K (reporting date: 2020-09-30), 10-K (reporting date: 2019-09-30), 10-K (reporting date: 2018-09-30), 10-K (reporting date: 2017-09-30).
1 2022 Calculation
ROA = 100 × Net income (loss) attributable to AmerisourceBergen Corporation ÷ Total assets
= 100 × 1,698,820 ÷ 56,560,616 = 3.00%
2 Click competitor name to see calculations.
The Return on Assets (ROA) for the period between 2017 and 2022 exhibits significant volatility, closely mirroring substantial fluctuations in net income. While the asset base expanded steadily over the majority of the analyzed timeframe, the efficiency of those assets in generating profit experienced a sharp disruption in 2020 before returning to positive territory.
- Net Income Fluctuations
- Net income demonstrated extreme variability, rising from 364.4 million USD in 2017 to a peak of 1.66 billion USD in 2018. This was followed by a decline in 2019 and a severe contraction in 2020, where the company reported a net loss of 3.41 billion USD. A recovery phase began in 2021, with net income returning to 1.54 billion USD and further increasing to 1.70 billion USD by 2022.
- Asset Base Expansion
- Total assets showed a consistent upward trend from September 30, 2017, through September 30, 2021, growing from 35.32 billion USD to a peak of 57.34 billion USD. A slight contraction occurred in 2022, with total assets settling at 56.56 billion USD. This growth indicates a significant expansion of the company's resource base over the six-year period.
- ROA Performance Trends
- The ROA peaked at 4.40% in 2018, reflecting the highest level of asset productivity during the period. The ratio plummeted to -7.70% in 2020, corresponding with the substantial net loss reported that year. Following this trough, the ROA recovered to 2.69% in 2021 and reached 3.00% in 2022, suggesting a stabilization of operational efficiency and a return to a positive correlation between asset growth and profitability.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.
How can I help you?